Company Overview and News
Good day, ladies and gentlemen, and welcome to the Equity Bancshares' Third Quarter 2018 Earnings Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. [Operator Instructions]. As a reminder, this call may be recorded.
CTBK MTSI EQBK
Good morning and welcome to the LegacyTexas Q3 2018 Earnings conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today’s presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your touchtone phone. To withdraw your question, please press star then two.
WFC WFCNP MTSI LTXB
Niu Technologies seems to have redefined urban mobility in China by designing a new smart electric two-wheeled vehicle that did not exist earlier.
The Fed minutes this week may well cement for investors the message that they’re on their own.
...Robert Duvall as gung-ho Lt. Colonel Kilgore in Francis Ford Coppola's classic Vietnam film "Apocalypse Now." In Kilgore's case, it was the "smell of victory" - not so for the market. Since Monday (10/8), it was napalm morning, noon and night for US equities, burning investors and incinerating portfolios. Panic set in bolstered by computer-generated algorithmic trading (if certain predetermined trigger points are hit, the computer says "sell" -forget the fundamentals - it sells).
MTSI JPM MMM
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
DowDuPont Inc. (NYSE: DWDP) saw its share price dive last week, along with just about every other equity on the market — or so it seemed. The company’s shares dropped 5.6% last week to take the stock down by 16.2% for the year to date.
JBK MTSI PG CATR GSC CAT TFG DWDP GSJ GS GLSSP GJS MMM
Stocks were indicated higher on Friday as overseas markets stabilized, but this is following sharp selling pressure this week in the major U.S. equity indexes. While the all-time highs are still within striking distance, investors have seen lower upside from buying immediately after the big market pullbacks in 2018 than in prior years. Now those investors also have to consider how to position their investments for the rest of the year and into 2019.
ATHTF FB FIT MTSI NFLX AMZN TWTR MS MMM GE GEC CARB ANTM BABA TRI GNE MSFT ANTX
Boeing Co.'s stock BA, -3.60% took a 3.5% dive in afternoon trade Wednesday, enough to make it the biggest drag in the Dow Jones Industrial Average DJIA, -1.61% The price decline of $13.62 was shaving about 92 points off the Dow's price, which was down 416 points. Regarding Boeing's delivery data released Tuesday, analyst Robert Stallard at Vertical Research Partners said Wednesday that the fact that monthly delivery rates for 737 and 787 aircraft were below the production rates means the company has "a lot to do if it is to hit its delivery forecast for this year of 810-815 aircraft.
MTSI NKE BOE BA
Goldman Sachs Group Inc. (NYSE: GS) saw its share price rise a bit last week, but the gain was not enough to lift the stock out of the Dow cellar. Goldman’s shares added 0.66% last week, but the stock is still down 11.4% for the year to date.
WMT GLSSP MS MMM PRU JBK TFG PFK BRK.A PRH PJH WFCNP MTSI PG GS WFC GSC DWDP GSJ GJS
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to MTSI / MACOM Technology Solutions Holdings, Inc. on message board site Silicon Investor.
|MicroTouch (MTSI): at or near bottom?||MicroTouch (MTSI): at or near bottom?||MicroTouch (MTSI): at or near bottom?|
as of ET